Combined magnetic resonance imaging and spectroscopy in the assessment of high grade prostate carcinoma in patients with elevated PSA: a single-institution experience of 356 patients.

[1]  G. De Meerleer,et al.  A qualitative approach to combined magnetic resonance imaging and spectroscopy in the diagnosis of prostate cancer. , 2010, European journal of radiology.

[2]  John Kurhanewicz,et al.  Combined magnetic resonance imaging and magnetic resonance spectroscopy imaging in the diagnosis of prostate cancer: a systematic review and meta-analysis. , 2009, European urology.

[3]  I. Tuerk,et al.  Comparing the Gleason prostate biopsy and Gleason prostatectomy grading system: the Lahey Clinic Medical Center experience and an international meta-analysis. , 2008, European urology.

[4]  M. Terris,et al.  Risk stratification of men with Gleason score 7 to 10 tumors by primary and secondary Gleason score: results from the SEARCH database. , 2007, Urology.

[5]  M. Jacobs,et al.  Choline metabolism in cancer: implications for diagnosis and therapy , 2006, Expert review of molecular diagnostics.

[6]  Ellen Ackerstaff,et al.  Choline phospholipid metabolism in cancer: consequences for molecular pharmaceutical interventions. , 2006, Molecular pharmaceutics.

[7]  Jason A Koutcher,et al.  Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy-initial experience. , 2005, Radiology.

[8]  M. Kattan,et al.  Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. , 2005, Radiology.

[9]  P. Carroll,et al.  Prostate depiction at endorectal MR spectroscopic imaging: investigation of a standardized evaluation system. , 2004, Radiology.

[10]  Arend Heerschap,et al.  Fast acquisition‐weighted three‐dimensional proton MR spectroscopic imaging of the human prostate , 2004, Magnetic resonance in medicine.

[11]  H. Hricak,et al.  Chronic prostatitis: MR imaging and 1H MR spectroscopic imaging findings--initial observations. , 2004, Radiology.

[12]  H. Schmid,et al.  Update on screening for prostate cancer with prostate-specific antigen. , 2004, Critical reviews in oncology/hematology.

[13]  P. Walsh,et al.  Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. , 2003, The Journal of urology.

[14]  Harry J de Koning,et al.  Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. , 2003, Journal of the National Cancer Institute.

[15]  Jose M. Silva,et al.  Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy , 2002, Oncogene.

[16]  J. Nelson,et al.  Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. , 2001, Cancer research.

[17]  D P Dearnaley,et al.  Effects of androgen deprivation on prostatic morphology and vascular permeability evaluated with mr imaging. , 2001, Radiology.

[18]  R. Franklin,et al.  The Intermediary Metabolism of the Prostate: A Key to Understanding the Pathogenesis and Progression of Prostate Malignancy , 2000, Oncology.

[19]  K. Taari,et al.  Magnetic resonance imaging of prostatic cancer: Does detection vary between high and low gleason score tumors? , 2000, The Prostate.

[20]  J. Epstein,et al.  Gleason score 2-4 adenocarcinoma of the prostate on needle biopsy: a diagnosis that should not be made. , 2000, The American journal of surgical pathology.

[21]  D. Chan,et al.  Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. , 1998, The Journal of urology.

[22]  P. Carroll,et al.  Hormonal ablation of prostatic cancer: effects on prostate morphology, tumor detection, and staging by endorectal coil MR imaging. , 1996, AJR. American journal of roentgenology.

[23]  R E Lenkinski,et al.  Current role of MR imaging in the staging of adenocarcinoma of the prostate. , 1993, Radiology.

[24]  J. Lewin,et al.  Prostatic carcinoma and benign prostatic hyperplasia: MR imaging with histopathologic correlation. , 1989, Radiology.

[25]  L Axel,et al.  Prostatic carcinoma and benign prostatic hyperplasia: correlation of high-resolution MR and histopathologic findings. , 1989, Radiology.

[26]  J. Kavanagh,et al.  Sodium, potassium, calcium, magnesium, zinc, citrate and chloride content of human prostatic and seminal fluid. , 1985, Journal of reproduction and fertility.

[27]  H. Hricak,et al.  Assessment of biologic aggressiveness of prostate cancer: correlation of MR signal intensity with Gleason grade after radical prostatectomy. , 2008, Radiology.

[28]  Consumer Protection,et al.  European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition--summary document. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  L. Nyström.  Epidemiological guidelines for quality assurance in breast cancer screening , 2006 .

[30]  L. Klotz.  Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer. , 2005, European urology.

[31]  M. Spraul,et al.  Ultra high field NMR spectroscopic studies on human seminal fluid, seminal vesicle and prostatic secretions. , 1994, Journal of pharmaceutical and biomedical analysis.